Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT

RCT (n=1,643) reports there were no statistically significant differences between the groups for 17 prostate cancer-specific (p = 0.48) and 169 all-cause (p = 0.87) deaths; and at 10-year median follow-up, there was no difference in disease-specific mortality.


NIHR Evidence